Back to top

Image: Bigstock

The Zacks Analyst Blog Highlights: AbbVie, Oracle, GlaxoSmithKline, Kroger and Southern

Read MoreHide Full Article

For Immediate Release

Chicago, IL – June 22, 2020 – announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include AbbVie Inc. (ABBV - Free Report) , Oracle Corporation (ORCL - Free Report) , GlaxoSmithKline plc (GSK - Free Report) , The Kroger Co. (KR - Free Report) and The Southern Company (SO - Free Report) .

Here are highlights from Friday’s Analyst Blog:

Top Analyst Reports for AbbVie, Oracle and GlaxoSmithKline

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including AbbVie Inc., Oracle Corporation and GlaxoSmithKline plc. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.

You can see all of today’s research reports here >>>

AbbVie’s shares have outperformed the Zacks Large Cap Pharmaceuticals industry over the past one-year period (+22.8% vs. +4%) on the back of the company's success in expanding labels of its cancer drugs, Imbruvica and Venclexta. In particular, Imbruvica has multi-billion-dollar potential. At the same time, AbbVie’s key drug, Humira continues to see strong demand trends in the United States. 

However, sales erosion due to direct biosimilar competition to Humira in international markets is a big headwind. Meanwhile, AbbVie expects slower new patient starts of physician-administered drugs to hurt sales in the second quarter.

(You can read the full research report on AbbVie here >>>)

Shares of Oracle have lagged the peer group lately, but the Zacks analyst believes that the company’s growing cloud business and the latest autonomous database is expected to boost its competitive position in the long haul. 

Strong adoption of cloud-based solutions, comprising NetSuite ERP, Fusion ERP and Fusion HCM, remained notable. In fact, 8x8 and Zoom Video Communications recently selected Oracle Cloud Infrastructure services to address business needs, which is a testament to the strength of its cloud offerings. Solid demand for Autonomous Database supported by ML is anticipated to also drive top line.

(You can read the full research report on Oracle here >>>)

GlaxoSmithKline’s shares have gained +22.8% over the past three months compared to the Zacks Large Cap Pharmaceuticals industry’s rise of +23.0%. The Zacks analysts sees that Glaxo’s three newest products, Trelegy Ellipta, Shingrix and Juluca, are doing well, particularly Shingrix. These products coupled with restructuring in the Consumer Health unit have strengthened Glaxo’s competitive position.

The Zacks analyst is further encouraged by the company’s initiative to focus on its oncology pipeline. In 2020, Glaxo expects at least six potential approvals in oncology, HIV, and respiratory areas. However, pricing pressure and competitive dynamics due to generic competition for key drug, Advair, are hampering sales of Glaxo’s respiratory products. Also, competitive pressure on HIV drugs has risen.

(You can read the full research report on GlaxoSmithKline here >>>)

Other noteworthy reports we are featuring today include The Kroger Co. and The Southern Company.

5 Stocks to Soar Past the Pandemic: In addition to the companies you learned about above, we invite you to learn about 5 cutting-edge stocks that could skyrocket from the exponential increase in demand for “stay at home” technologies. This could be one of the biggest buying opportunities of the decade.

See the 5 high-tech stocks now>>

Media Contact                                               

Zacks Investment Research

800-767-3771 ext. 9339                                                                  

Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit for information about the performance numbers displayed in this press release.

Published in